Avoid common mistakes on your manuscript.
1 Correction to: Drugs https://doi.org/10.1007/s40265-022-01797-x
An error was introduced by the publisher during the typesetting process.
Table 3 ‘Summary of AEs over the full study period (PUNCH CD3 safety population; N = 267)’
Second column heading, which currently reads ‘Blinded Placebo (n = 870)’
Should read:
‘Blinded Placebo (n = 87)’
The original article has been corrected.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
About this article
Cite this article
Khanna, S., Assi, M., Lee, C. et al. Publisher Correction: Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection. Drugs 82, 1539 (2022). https://doi.org/10.1007/s40265-022-01805-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40265-022-01805-0